Here's Why Ardelyx (ARDX) Could be Great Choice for a Bottom Fisher — Oct 18th, 2024

Shares of Ardelyx (ARDX) have been struggling lately and have lost 12.5% over the past two weeks. However, a hammer chart pattern was formed in its last trading session, which could mean that the stock found support with bulls being able to counteract the bears. So, it could witness a tren...

Ardelyx to Report Third Quarter 2024 Financial Results on October 31, 2024 — Oct 17th, 2024

Ardelyx, Inc. Conference call scheduled for 4:30 p.m. Eastern Time WALTHAM, Mass., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet sign...

Here's Why Ardelyx (ARDX) Could be Great Choice for a Bottom Fisher — Oct 18th, 2024

Shares of Ardelyx (ARDX) have been struggling lately and have lost 12.5% over the past two weeks. However, a hammer chart pattern was formed in its last trading session, which could mean that the stock found support with bulls being able to counteract the bears. So, it could witness a tren...

Here's Why Ardelyx (ARDX) Could be Great Choice for a Bottom Fisher — Oct 18th, 2024

Shares of Ardelyx (ARDX) have been struggling lately and have lost 12.5% over the past two weeks. However, a hammer chart pattern was formed in its last trading session, which could mean that the stock found support with bulls being able to counteract the bears. So, it could witness a tren...

Even though Ardelyx (NASDAQ:ARDX) has lost US$210m market cap in last 7 days, shareholders are still up 352% over 3 years — Oct 9th, 2024

Ardelyx, Inc. (NASDAQ:ARDX) shareholders might be concerned after seeing the share price drop 13% in the last week. But that doesn't displace its brilliant performance over three years. The longer term view reveals that the share price is up 352% in that period. So you might argue that the...

Ardelyx Inc (ARDX) Q2 2024 Earnings Call Highlights: Revenue Surge and Strategic Challenges — Oct 9th, 2024

Total Revenue: $73.2 million in Q2 2024, up from $22.3 million in Q2 2023. Net Product Sales Revenue: $72.6 million in Q2 2024, compared to $18.3 million in Q2 2023. IBSRELA Revenue: $35.4 million in Q2 2024, nearly doubling from $18.3 million in Q2 2023. XPHOZAH Revenue: $37.1 million in ...

Ardelyx Announces Publication of a Review Article Exploring the Patient Burden and Therapeutic Landscape of IBS-C in the U.S. in Clinical and Experimental Gastroenterology — Oct 9th, 2024

Ardelyx, Inc. WALTHAM, Mass., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced the recen...

Here's Why Ardelyx (ARDX) Could be Great Choice for a Bottom Fisher — Oct 18th, 2024

Shares of Ardelyx (ARDX) have been struggling lately and have lost 12.5% over the past two weeks. However, a hammer chart pattern was formed in its last trading session, which could mean that the stock found support with bulls being able to counteract the bears. So, it could witness a tren...

Ardelyx to Report Third Quarter 2024 Financial Results on October 31, 2024 — Oct 17th, 2024

Ardelyx, Inc. Conference call scheduled for 4:30 p.m. Eastern Time WALTHAM, Mass., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet sign...

Ardelyx Inc (ARDX) Q2 2024 Earnings Call Highlights: Revenue Surge and Strategic Challenges — Oct 9th, 2024

Total Revenue: $73.2 million in Q2 2024, up from $22.3 million in Q2 2023. Net Product Sales Revenue: $72.6 million in Q2 2024, compared to $18.3 million in Q2 2023. IBSRELA Revenue: $35.4 million in Q2 2024, nearly doubling from $18.3 million in Q2 2023. XPHOZAH Revenue: $37.1 million in ...

Ardelyx Announces Publication of a Review Article Exploring the Patient Burden and Therapeutic Landscape of IBS-C in the U.S. in Clinical and Experimental Gastroenterology — Oct 9th, 2024

Ardelyx, Inc. WALTHAM, Mass., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced the recen...

Ardelyx to Present Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) for Adults with Chronic Kidney Disease on Dialysis at the American Society of Nephrology’s Kidney Week — Oct 15th, 2024

Ardelyx, Inc. WALTHAM, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that addi...

Ardelyx to Present Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) for Adults with Chronic Kidney Disease on Dialysis at the American Society of Nephrology’s Kidney Week — Oct 15th, 2024

Ardelyx, Inc. WALTHAM, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that addi...

Ardelyx to Present Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) for Adults with Chronic Kidney Disease on Dialysis at the American Society of Nephrology’s Kidney Week — Oct 15th, 2024

Ardelyx, Inc. WALTHAM, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that addi...

Ardelyx Announces Publication of a Review Article Exploring the Patient Burden and Therapeutic Landscape of IBS-C in the U.S. in Clinical and Experimental Gastroenterology — Oct 9th, 2024

Ardelyx, Inc. WALTHAM, Mass., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced the recen...

Ardelyx to Report Third Quarter 2024 Financial Results on October 31, 2024 — Oct 17th, 2024

Ardelyx, Inc. Conference call scheduled for 4:30 p.m. Eastern Time WALTHAM, Mass., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet sign...

Even though Ardelyx (NASDAQ:ARDX) has lost US$210m market cap in last 7 days, shareholders are still up 352% over 3 years — Oct 9th, 2024

Ardelyx, Inc. (NASDAQ:ARDX) shareholders might be concerned after seeing the share price drop 13% in the last week. But that doesn't displace its brilliant performance over three years. The longer term view reveals that the share price is up 352% in that period. So you might argue that the...

Ardelyx Announces Publication of a Review Article Exploring the Patient Burden and Therapeutic Landscape of IBS-C in the U.S. in Clinical and Experimental Gastroenterology — Oct 9th, 2024

Ardelyx, Inc. WALTHAM, Mass., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced the recen...

Here's Why Ardelyx (ARDX) Could be Great Choice for a Bottom Fisher — Oct 18th, 2024

Shares of Ardelyx (ARDX) have been struggling lately and have lost 12.5% over the past two weeks. However, a hammer chart pattern was formed in its last trading session, which could mean that the stock found support with bulls being able to counteract the bears. So, it could witness a tren...

Ardelyx Announces Publication of a Review Article Exploring the Patient Burden and Therapeutic Landscape of IBS-C in the U.S. in Clinical and Experimental Gastroenterology — Oct 9th, 2024

Ardelyx, Inc. WALTHAM, Mass., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced the recen...

Ardelyx Inc (ARDX) Q2 2024 Earnings Call Highlights: Revenue Surge and Strategic Challenges — Oct 9th, 2024

Total Revenue: $73.2 million in Q2 2024, up from $22.3 million in Q2 2023. Net Product Sales Revenue: $72.6 million in Q2 2024, compared to $18.3 million in Q2 2023. IBSRELA Revenue: $35.4 million in Q2 2024, nearly doubling from $18.3 million in Q2 2023. XPHOZAH Revenue: $37.1 million in ...

Ardelyx to Present Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) for Adults with Chronic Kidney Disease on Dialysis at the American Society of Nephrology’s Kidney Week — Oct 15th, 2024

Ardelyx, Inc. WALTHAM, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that addi...

Even though Ardelyx (NASDAQ:ARDX) has lost US$210m market cap in last 7 days, shareholders are still up 352% over 3 years — Oct 9th, 2024

Ardelyx, Inc. (NASDAQ:ARDX) shareholders might be concerned after seeing the share price drop 13% in the last week. But that doesn't displace its brilliant performance over three years. The longer term view reveals that the share price is up 352% in that period. So you might argue that the...

Here's Why Ardelyx (ARDX) Could be Great Choice for a Bottom Fisher — Oct 18th, 2024

Shares of Ardelyx (ARDX) have been struggling lately and have lost 12.5% over the past two weeks. However, a hammer chart pattern was formed in its last trading session, which could mean that the stock found support with bulls being able to counteract the bears. So, it could witness a tren...

Ardelyx to Report Third Quarter 2024 Financial Results on October 31, 2024 — Oct 17th, 2024

Ardelyx, Inc. Conference call scheduled for 4:30 p.m. Eastern Time WALTHAM, Mass., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet sign...

Ardelyx to Present Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) for Adults with Chronic Kidney Disease on Dialysis at the American Society of Nephrology’s Kidney Week — Oct 15th, 2024

Ardelyx, Inc. WALTHAM, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that addi...

Ardelyx to Report Third Quarter 2024 Financial Results on October 31, 2024 — Oct 17th, 2024

Ardelyx, Inc. Conference call scheduled for 4:30 p.m. Eastern Time WALTHAM, Mass., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet sign...

Here's Why Ardelyx (ARDX) Could be Great Choice for a Bottom Fisher — Oct 18th, 2024

Shares of Ardelyx (ARDX) have been struggling lately and have lost 12.5% over the past two weeks. However, a hammer chart pattern was formed in its last trading session, which could mean that the stock found support with bulls being able to counteract the bears. So, it could witness a tren...

Here's Why Ardelyx (ARDX) Could be Great Choice for a Bottom Fisher — Oct 18th, 2024

Shares of Ardelyx (ARDX) have been struggling lately and have lost 12.5% over the past two weeks. However, a hammer chart pattern was formed in its last trading session, which could mean that the stock found support with bulls being able to counteract the bears. So, it could witness a tren...

Here's Why Ardelyx (ARDX) Could be Great Choice for a Bottom Fisher — Oct 18th, 2024

Shares of Ardelyx (ARDX) have been struggling lately and have lost 12.5% over the past two weeks. However, a hammer chart pattern was formed in its last trading session, which could mean that the stock found support with bulls being able to counteract the bears. So, it could witness a tren...

Even though Ardelyx (NASDAQ:ARDX) has lost US$210m market cap in last 7 days, shareholders are still up 352% over 3 years — Oct 9th, 2024

Ardelyx, Inc. (NASDAQ:ARDX) shareholders might be concerned after seeing the share price drop 13% in the last week. But that doesn't displace its brilliant performance over three years. The longer term view reveals that the share price is up 352% in that period. So you might argue that the...

Ardelyx to Report Third Quarter 2024 Financial Results on October 31, 2024 — Oct 17th, 2024

Ardelyx, Inc. Conference call scheduled for 4:30 p.m. Eastern Time WALTHAM, Mass., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet sign...

Even though Ardelyx (NASDAQ:ARDX) has lost US$210m market cap in last 7 days, shareholders are still up 352% over 3 years — Oct 9th, 2024

Ardelyx, Inc. (NASDAQ:ARDX) shareholders might be concerned after seeing the share price drop 13% in the last week. But that doesn't displace its brilliant performance over three years. The longer term view reveals that the share price is up 352% in that period. So you might argue that the...

Ardelyx Announces Publication of a Review Article Exploring the Patient Burden and Therapeutic Landscape of IBS-C in the U.S. in Clinical and Experimental Gastroenterology — Oct 9th, 2024

Ardelyx, Inc. WALTHAM, Mass., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced the recen...

Here's Why Ardelyx (ARDX) Could be Great Choice for a Bottom Fisher — Oct 18th, 2024

Shares of Ardelyx (ARDX) have been struggling lately and have lost 12.5% over the past two weeks. However, a hammer chart pattern was formed in its last trading session, which could mean that the stock found support with bulls being able to counteract the bears. So, it could witness a tren...

Ardelyx Inc (ARDX) Q2 2024 Earnings Call Highlights: Revenue Surge and Strategic Challenges — Oct 9th, 2024

Total Revenue: $73.2 million in Q2 2024, up from $22.3 million in Q2 2023. Net Product Sales Revenue: $72.6 million in Q2 2024, compared to $18.3 million in Q2 2023. IBSRELA Revenue: $35.4 million in Q2 2024, nearly doubling from $18.3 million in Q2 2023. XPHOZAH Revenue: $37.1 million in ...

Ardelyx to Report Third Quarter 2024 Financial Results on October 31, 2024 — Oct 17th, 2024

Ardelyx, Inc. Conference call scheduled for 4:30 p.m. Eastern Time WALTHAM, Mass., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet sign...

Ardelyx to Present Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) for Adults with Chronic Kidney Disease on Dialysis at the American Society of Nephrology’s Kidney Week — Oct 15th, 2024

Ardelyx, Inc. WALTHAM, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that addi...

Even though Ardelyx (NASDAQ:ARDX) has lost US$210m market cap in last 7 days, shareholders are still up 352% over 3 years — Oct 9th, 2024

Ardelyx, Inc. (NASDAQ:ARDX) shareholders might be concerned after seeing the share price drop 13% in the last week. But that doesn't displace its brilliant performance over three years. The longer term view reveals that the share price is up 352% in that period. So you might argue that the...

Even though Ardelyx (NASDAQ:ARDX) has lost US$210m market cap in last 7 days, shareholders are still up 352% over 3 years — Oct 9th, 2024

Ardelyx, Inc. (NASDAQ:ARDX) shareholders might be concerned after seeing the share price drop 13% in the last week. But that doesn't displace its brilliant performance over three years. The longer term view reveals that the share price is up 352% in that period. So you might argue that the...

Ardelyx Inc (ARDX) Q2 2024 Earnings Call Highlights: Revenue Surge and Strategic Challenges — Oct 9th, 2024

Total Revenue: $73.2 million in Q2 2024, up from $22.3 million in Q2 2023. Net Product Sales Revenue: $72.6 million in Q2 2024, compared to $18.3 million in Q2 2023. IBSRELA Revenue: $35.4 million in Q2 2024, nearly doubling from $18.3 million in Q2 2023. XPHOZAH Revenue: $37.1 million in ...

Ardelyx to Present Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) for Adults with Chronic Kidney Disease on Dialysis at the American Society of Nephrology’s Kidney Week — Oct 15th, 2024

Ardelyx, Inc. WALTHAM, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that addi...

Ardelyx Inc (ARDX) Q2 2024 Earnings Call Highlights: Revenue Surge and Strategic Challenges — Oct 9th, 2024

Total Revenue: $73.2 million in Q2 2024, up from $22.3 million in Q2 2023. Net Product Sales Revenue: $72.6 million in Q2 2024, compared to $18.3 million in Q2 2023. IBSRELA Revenue: $35.4 million in Q2 2024, nearly doubling from $18.3 million in Q2 2023. XPHOZAH Revenue: $37.1 million in ...

Ardelyx Announces Publication of a Review Article Exploring the Patient Burden and Therapeutic Landscape of IBS-C in the U.S. in Clinical and Experimental Gastroenterology — Oct 9th, 2024

Ardelyx, Inc. WALTHAM, Mass., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced the recen...

Even though Ardelyx (NASDAQ:ARDX) has lost US$210m market cap in last 7 days, shareholders are still up 352% over 3 years — Oct 9th, 2024

Ardelyx, Inc. (NASDAQ:ARDX) shareholders might be concerned after seeing the share price drop 13% in the last week. But that doesn't displace its brilliant performance over three years. The longer term view reveals that the share price is up 352% in that period. So you might argue that the...

Ardelyx to Report Third Quarter 2024 Financial Results on October 31, 2024 — Oct 17th, 2024

Ardelyx, Inc. Conference call scheduled for 4:30 p.m. Eastern Time WALTHAM, Mass., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet sign...

Ardelyx to Present Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) for Adults with Chronic Kidney Disease on Dialysis at the American Society of Nephrology’s Kidney Week — Oct 15th, 2024

Ardelyx, Inc. WALTHAM, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that addi...

Ardelyx to Report Third Quarter 2024 Financial Results on October 31, 2024 — Oct 17th, 2024

Ardelyx, Inc. Conference call scheduled for 4:30 p.m. Eastern Time WALTHAM, Mass., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet sign...

Ardelyx Inc (ARDX) Q2 2024 Earnings Call Highlights: Revenue Surge and Strategic Challenges — Oct 9th, 2024

Total Revenue: $73.2 million in Q2 2024, up from $22.3 million in Q2 2023. Net Product Sales Revenue: $72.6 million in Q2 2024, compared to $18.3 million in Q2 2023. IBSRELA Revenue: $35.4 million in Q2 2024, nearly doubling from $18.3 million in Q2 2023. XPHOZAH Revenue: $37.1 million in ...

Ardelyx Inc (ARDX) Q2 2024 Earnings Call Highlights: Revenue Surge and Strategic Challenges — Oct 9th, 2024

Total Revenue: $73.2 million in Q2 2024, up from $22.3 million in Q2 2023. Net Product Sales Revenue: $72.6 million in Q2 2024, compared to $18.3 million in Q2 2023. IBSRELA Revenue: $35.4 million in Q2 2024, nearly doubling from $18.3 million in Q2 2023. XPHOZAH Revenue: $37.1 million in ...